

Neuralstem, Inc.  
Form 8-K  
September 12, 2016

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**Form 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): September 12, 2016

**Neuralstem, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**

(State or Other Jurisdiction of  
Incorporation)

**001-33672**

(Commission File Number)

**52-2007292**

(I.R.S. Employer Identification  
Number)

**20271 Goldenrod Lane, 2nd Floor, Germantown,  
Maryland 20876**

(Address of Principal Executive Offices) (Zip Code)

**301-366-4960**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
]  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
]  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
]  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
]
-

**Item 8.01. Other Events.**

On September 12, 2016, Neuralstem, Inc. (the “Company”) announced that Dr. Karl Johe, Ph.D., the Company’s chief scientific officer presented the poster “Therapeutic Efficacy of NSI-189 in Diabetic Mice,” at the Annual Meeting of the Diabetic Neuropathy Study Group of the EASD (European Association for the Study of Diabetes), held in Bucharest, Romania, on September 11, 2016. A copy of the press release is attached to this report as Exhibit 99.01.

**Item 9.01. Financial Statements and Exhibits.**

<b>Exhibit No.</b>	<b>Description</b>
Exhibit 99.01	Press Release dated September 12, 2016

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Neuralstem, Inc.**

Date: September 12, 2016

By: /s/ Richard Daly  
Richard Daly  
Chief Executive Officer

---

**INDEX OF EXHIBITS**

<b>Exhibit No.</b>	<b>Description</b>
Exhibit 99.01	Press Release dated September 12, 2016